News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neuren Pharmaceuticals Limited to Move to Phase 2 Trial of NNZ-2566 on TBI
September 20, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sydney, Sep 20, 2007 -- Neuren Pharmaceuticals has completed cohorts 1 and 2 of its Phase 1b trial to test the safety, tolerability and pharmacokinetic action of NNZ-2566 as a compound to treat traumatic brain injury (TBI).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Australia
MORE ON THIS TOPIC
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
·
1 min read
·
Heather McKenzie
Rare diseases
Harmony Freezes Cannabidiol Gel After Phase III Miss in Fragile X Syndrome
November 5, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters
November 4, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold
November 3, 2025
·
1 min read
·
Annalee Armstrong
